中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
23期
3616-3618
,共3页
呼吸机%尼可刹米%呼吸衰竭
呼吸機%尼可剎米%呼吸衰竭
호흡궤%니가찰미%호흡쇠갈
Ventilator%Nikethamide%Respiratory failure
目的：观察采用经鼻双水平正压（BiPAP）呼吸机与尼可刹米联合应用治疗 COPD 并Ⅱ型呼吸衰竭的临床疗效及安全性。方法将 COPD 合并Ⅱ型呼吸衰竭患者共76例选为研究对象，采用单盲、随机法将其分为两组，每组38例。对照组予尼可刹米治疗，观察组联合应用 BiPAP 呼吸机辅助通气治疗。分析临床治疗效果及不良反应情况并进行组间比较。结果观察组总有效率为92．11％，对照组总有效率为68．42％，组间差异有统计学意义（χ2＝10．54，P ＜0．05）。治疗后观察组患者 HR[（94．28±7．62）次／min]和 RR [（13.27±4.41）次／min]均较治疗前明显减少（t ＝8．02，8．04，均 P ＜0．05），且均显著低于对照组（t ＝7．54，6．88，均 P ＜0．05）。治疗后观察组患者 pH 值（7．39±0．06）、PaO2（96．31±5．44）mmHg、SaO2（98.42±6.87）％均较治疗前明显增加（t ＝7．56、7．76、7．45，均 P ＜0．05），PaCO2（57．36±4．98）mmHg 较治疗前明显减少（t ＝7．54，P ＜0.05），且上述指标与对照组比较差异均有统计学意义（t ＝6．56、7．02、6．73、7．32，均 P ＜0.05）。两组不良反应发生率差异无统计学意义（χ2＝2．14，P ＞0．05）。结论BiPAP 呼吸机与尼可刹米联合治疗 COPD 合并Ⅱ型呼吸衰竭有显著疗效，且有较高安全性，值得临床借鉴和推广应用。
目的：觀察採用經鼻雙水平正壓（BiPAP）呼吸機與尼可剎米聯閤應用治療 COPD 併Ⅱ型呼吸衰竭的臨床療效及安全性。方法將 COPD 閤併Ⅱ型呼吸衰竭患者共76例選為研究對象，採用單盲、隨機法將其分為兩組，每組38例。對照組予尼可剎米治療，觀察組聯閤應用 BiPAP 呼吸機輔助通氣治療。分析臨床治療效果及不良反應情況併進行組間比較。結果觀察組總有效率為92．11％，對照組總有效率為68．42％，組間差異有統計學意義（χ2＝10．54，P ＜0．05）。治療後觀察組患者 HR[（94．28±7．62）次／min]和 RR [（13.27±4.41）次／min]均較治療前明顯減少（t ＝8．02，8．04，均 P ＜0．05），且均顯著低于對照組（t ＝7．54，6．88，均 P ＜0．05）。治療後觀察組患者 pH 值（7．39±0．06）、PaO2（96．31±5．44）mmHg、SaO2（98.42±6.87）％均較治療前明顯增加（t ＝7．56、7．76、7．45，均 P ＜0．05），PaCO2（57．36±4．98）mmHg 較治療前明顯減少（t ＝7．54，P ＜0.05），且上述指標與對照組比較差異均有統計學意義（t ＝6．56、7．02、6．73、7．32，均 P ＜0.05）。兩組不良反應髮生率差異無統計學意義（χ2＝2．14，P ＞0．05）。結論BiPAP 呼吸機與尼可剎米聯閤治療 COPD 閤併Ⅱ型呼吸衰竭有顯著療效，且有較高安全性，值得臨床藉鑒和推廣應用。
목적：관찰채용경비쌍수평정압（BiPAP）호흡궤여니가찰미연합응용치료 COPD 병Ⅱ형호흡쇠갈적림상료효급안전성。방법장 COPD 합병Ⅱ형호흡쇠갈환자공76례선위연구대상，채용단맹、수궤법장기분위량조，매조38례。대조조여니가찰미치료，관찰조연합응용 BiPAP 호흡궤보조통기치료。분석림상치료효과급불량반응정황병진행조간비교。결과관찰조총유효솔위92．11％，대조조총유효솔위68．42％，조간차이유통계학의의（χ2＝10．54，P ＜0．05）。치료후관찰조환자 HR[（94．28±7．62）차／min]화 RR [（13.27±4.41）차／min]균교치료전명현감소（t ＝8．02，8．04，균 P ＜0．05），차균현저저우대조조（t ＝7．54，6．88，균 P ＜0．05）。치료후관찰조환자 pH 치（7．39±0．06）、PaO2（96．31±5．44）mmHg、SaO2（98.42±6.87）％균교치료전명현증가（t ＝7．56、7．76、7．45，균 P ＜0．05），PaCO2（57．36±4．98）mmHg 교치료전명현감소（t ＝7．54，P ＜0.05），차상술지표여대조조비교차이균유통계학의의（t ＝6．56、7．02、6．73、7．32，균 P ＜0.05）。량조불량반응발생솔차이무통계학의의（χ2＝2．14，P ＞0．05）。결론BiPAP 호흡궤여니가찰미연합치료 COPD 합병Ⅱ형호흡쇠갈유현저료효，차유교고안전성，치득림상차감화추엄응용。
Objective To observe the efficacy and safety of BiPAP ventilator combined with nikethamide for the chronic obstructive pulmonary disease (COPD)complicated with type II respiratory failure.Methods 76 COPD patients complicated with type II respiratory failure were selected as the research subjects,they were randomly divided into two groups by single blind and randomized method,38 cases in each group.The control group was treated with nikethamide therapy,while the observation group used BiPAP combined with mechanical ventilation therapy.The clinical therapeutic effect and adverse reactions were analyzed and compared in the two groups.Results The total effective rate in the observation group was 92.11%,which was significantly higher than 68.42% in the control group (χ2 =10.54,P <0.05).After treatment,the HR and RR of the observation group were (94.28 ±7.62)/min, (13.27 ±4.41)/min,which were significantly decreased than before treatment (t =8.02,8.04,all P <0.05),and which were significantly lower than those in the control group (t =7.54,6.88,P <0.05).After treatment,the pH (7.39 ±0.06),PaO2 (96.31 ±5.44)mmHg,SaO2 (98.42 ±6.87)% in the observation group were significantly increased (t =7.56,7.76,7.45,all P <0.05),PaCO2 (57.36 ±4.98)mmHg was significantly decreased (t =7.54, P <0.05),which had significant differences with the control group (t =6.56,7.02,6.73,7.32,all P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups (χ2 =2.14,P >0.05). Conclusion BiPAP ventilator combined with nikethamide meters has remarkable curative effect and high safety in treatment of COPD patients complicated with type II respiratory failure,which is worthy of clinical reference and popularization.
